<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121901</url>
  </required_header>
  <id_info>
    <org_study_id>EPEPPS-06-2005</org_study_id>
    <nct_id>NCT00121901</nct_id>
  </id_info>
  <brief_title>Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <brief_summary>
    <textblock>
      Post-ERCP pancreatitis can be a serious complication to ERCP. Two studies have shown a&#xD;
      promising preventive effect of glyceryl nitrate. This study should provide a final answer to&#xD;
      the clinical question: Does glyceryl nitrate prevent post-ERCP pancreatitis? The study is a&#xD;
      prospective, randomized, double blind, placebo-controlled multicenter trial. The&#xD;
      investigators intend to include 1600 patients from Norway, Sweden, Denmark, and France.&#xD;
&#xD;
      The patients will receive either placebo or a glyceryl nitrate patch (15 mg/24 hours).&#xD;
      Follow-up will occur after 7 days. The primary outcome measure will be post-ERCP&#xD;
      pancreatitis, and secondary outcome measures will be mild, moderate and severe pancreatitis;&#xD;
      post procedure pancreatitis-related mortality; and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project:&#xD;
&#xD;
      This study will compare glyceryl nitrate (GN) treatment to non-active treatment for the&#xD;
      prevention of post-ERCP acute pancreatitis, which is an inflammation of the pancreas that can&#xD;
      occur after a procedure known as ERCP.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      ERCP (endoscopic retrograde cholangiopancreaticography) is an examination of the pancreas by&#xD;
      which it is possible to perform therapeutic measures such as stone removal from the common&#xD;
      bile duct and visualisation of the pancreas. Inflammation of the pancreas after the ERCP&#xD;
      procedure (called: post-ERCP pancreatitis) is the most feared and common complication of the&#xD;
      ERCP. It occurs in 1-40% of patients, with rates of 5% or more being more typical. Currently,&#xD;
      the background of post-ERCP pancreatitis is poorly known.&#xD;
&#xD;
      Attempts at preventing post-ERCP pancreatitis have been carried out through a change to&#xD;
      low-risk techniques, by avoiding high-risk patients, and by use of pharmacological&#xD;
      prophylaxis.&#xD;
&#xD;
      Glyceryl Nitrate:&#xD;
&#xD;
      Glyceryl nitrate is a well-known medicine used for many years in other diseases. Possible&#xD;
      side effects are headache and low blood pressure. Other side effects such as dizziness,&#xD;
      tiredness, nausea, local redness at the application site and allergic reactions of the skin&#xD;
      are rare.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      The purpose of this study is to document that pre-treatment with GN is effective in&#xD;
      preventing post-ERCP pancreatitis. In two earlier GN studies, sample sizes were relatively&#xD;
      small (less than one hundred) and the rates of post-ERCP pancreatitis in the control group&#xD;
      were quite high (15-17%). Therefore, further studies are needed to confirm the promising&#xD;
      effect of GN in the prophylaxis of post-ERCP pancreatitis.&#xD;
&#xD;
      Participants:&#xD;
&#xD;
      The study includes every patient undergoing ERCP above the age of 18 years. Patients are&#xD;
      excluded if they have active acute pancreatitis, previous sphincterotomy (cut in the&#xD;
      sphincter at the end of the biliary and pancreatic ducts in the duodenum) or chronic&#xD;
      pancreatitis with calcifications. Also, patients may not take sildenafil (Viagra) as GN&#xD;
      should not be taken together with sildenafil. Patients allergic to glyceryl nitrate or glue&#xD;
      should not be included. Patients with constrictive pericarditis (inflammation and fibrosis in&#xD;
      the sack around the heart); pericardial tamponade (blood or liquor in the sack around the&#xD;
      heart); low blood pressure; aortic stenosis (stenosis of the aortic valve); hypertrophic&#xD;
      obstructive cardiomyopathy (a special disease with thickness of the heart); mitral stenosis&#xD;
      (stenosis of the mitral valve); anemia (low hemoglobin); and untreated hypothyroidism&#xD;
      (thyroid disease) are excluded because these are other diseases to which glyceryl nitrate&#xD;
      should not be used. Pregnant women are excluded. Patients can only be included once.&#xD;
&#xD;
      Practical:&#xD;
&#xD;
      Patients have been preparing for the study as if it was a normal procedure. Prior to the&#xD;
      procedure, patients will be asked to participate in the study. If the patients accept, after&#xD;
      oral and written consent, they will receive either a GN patch or non-active patch on the&#xD;
      chestwall 40-60 minutes prior to the ERCP procedure.&#xD;
&#xD;
      A canula is inserted in a cubital vein for medication. The ERCP is initiated, and patients&#xD;
      are observed afterwards according to local practice, which is typically 3 hours. Patients are&#xD;
      asked to fill out a letter with questions related to symptoms of pancreatitis (pain, fever,&#xD;
      nausea, vomiting, hospitalization) to send to the investigating center after 7 days. If&#xD;
      patients do not send the letter they will be contacted by phone within 14 days.&#xD;
&#xD;
      Interim analysis:&#xD;
&#xD;
      An interim analysis will be made, when 800 patients have been included. The study will stop,&#xD;
      if 1) the interim analysis shows a significant higher mortality in one group than in the&#xD;
      other or 2) if the study has proceeded more than 2 years.&#xD;
&#xD;
      Economy:&#xD;
&#xD;
      The project is a multicenter trial of the European Post-ERCP Pancreatitis Preventing Study&#xD;
      Group. This local project is located at XX-department. No commercial interests are involved.&#xD;
      The investigators/authors work for free against authorship. Finances are sought through funds&#xD;
      for research.&#xD;
&#xD;
      References:&#xD;
&#xD;
        1. Freeman M. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP&#xD;
           2002;3(6):169-176.&#xD;
&#xD;
        2. Demols A, Deviere J. New frontiers in the pharmacological prevention of post-ERCP&#xD;
           pancreatitis: the cytokines. JOP 2003; 4(1):49-57.&#xD;
&#xD;
        3. Testoni P. Preventing post-ERCP pancreatitis: where are we?. JOP 2003; 4(1):22-32.&#xD;
&#xD;
        4. Mariani A. Pharmacological prevention of post-ERCP pancreatitis:which therapy is best?.&#xD;
           JOP 2003; 4(1):68-74.&#xD;
&#xD;
        5. Murray B, Carter R et al. Diclofenac reduces the incidence of acute pancreatitis after&#xD;
           endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124:1786-1791.&#xD;
&#xD;
        6. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on&#xD;
           pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion&#xD;
           1993; 54:105-11.&#xD;
&#xD;
        7. Sudhindran S, Bromwich E et al. Prospective randomized double-blind placebo-controlled&#xD;
           trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreaticography-induced&#xD;
           pancreatitis. British J of Surg 2001; 88:1178-1182.&#xD;
&#xD;
        8. Moreto M, Zaballa M. et al. Transdermal glyceryl trinitrate for prevention of post-ERCP&#xD;
           pancreatitis: a randomized double-blind trial. Gastrointest Endoscopy 2003;57:1-7.&#xD;
&#xD;
        9. Harrison et al. Bioequivalence comparison of two drug-in-adhesive transdermal&#xD;
           nitroglycerine patches. Am J Ther 1996;3:580-585.&#xD;
&#xD;
       10. Pande H, Thuluvath PJ. Pharmacological prevention of post-endoscopic retrograde&#xD;
           cholangiopancreatography pancreatitis. Drugs 2003;63(17):1799-1812.&#xD;
&#xD;
       11. Freeman ML. Prevention of post-ERCP pancreatitis: Pharmacologic solution or patient&#xD;
           selection and pancreatic stents? Gastroenterology 2003;124(7):1977-1980.&#xD;
&#xD;
       12. Cotton PB, Lehman G, Vennes J, Geenen JE, et al. Endoscopic sphincterotomy complications&#xD;
           and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-393.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute pancreatitis within 7 days after the ERCP procedure. (An independent committee at each center will retrospectively judge whether patients have had post-ERCP pancreatitis or not in respect to a specific definition.)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>mild, moderate, and severe pancreatitis as a criterion proposed by Cotton et al [12]</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post procedure pancreatitis-related mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (severe and non-severe such as headache, dizziness, hypotension, hypersensibility, and others)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Pancreatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyceryl nitrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients (men and women) more than 18 years old who are going to have an ERCP&#xD;
             procedure performed at the different centers from September 1, 2004 to about January&#xD;
             31, 2005 will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Before the study: active acute pancreatitis (defined as: acute upper abdominal pain&#xD;
             and S-amylases x 3 upper normal limit OR upper abdominal pain + radiological findings&#xD;
             [CAT-/MR-scan] consistent with acute pancreatitis OR pathoanatomical findings&#xD;
             consistent with acute pancreatitis by surgery)&#xD;
&#xD;
          -  Known previous sphincterotomy&#xD;
&#xD;
          -  Chronic pancreatitis with known calcifications&#xD;
&#xD;
          -  Hypotension (definition: systolic blood pressure &lt; 100 mmHg)&#xD;
&#xD;
          -  Anemia, men/women (hemoglobin &lt; 6 mmol/l or &lt;9.7 g/dl)&#xD;
&#xD;
          -  Constrictive pericarditis&#xD;
&#xD;
          -  Pericardial tamponade&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy, aortic stenosis&#xD;
&#xD;
          -  Mitral stenosis sildenafil within 24 hours before the ERCP procedure and 24 hours&#xD;
             after the procedure&#xD;
&#xD;
          -  Hypersensibility to nitroglycerine&#xD;
&#xD;
          -  Hypersensibility to the applied glue on the patch&#xD;
&#xD;
          -  Known untreated hypothyroidism&#xD;
&#xD;
          -  Pregnancy or a potential to become pregnant, i.e. those who are not using safe&#xD;
             contraception (intrauterine device [IUD] or oral contraception)&#xD;
&#xD;
          -  Included earlier in the study&#xD;
&#xD;
          -  Exchange of stent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla Nøjgaard Nøjgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenheden, Hvidovre Hospital, Kettegård Alle 30, 2650 Hvidovre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical and Surgical Gastroenterology, KAS Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Medical Gastroenterology F, KAS Gentofte</name>
      <address>
        <city>Copenhagen</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenheden, Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Hvidovre</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>København Ø</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Køge County Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Gastroenterology S, Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Serv Gastroenterologie Hopital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <state>Marseille Cedex 09</state>
        <zip>F-13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div of Gastroenterology, dept. of Int Medicine Affiliated Hospital University of Oslo, Østfold Fredrikstad</name>
      <address>
        <city>Fredrikstad</city>
        <zip>N-1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Fonna HF Haugesund Sjukehus Kirurgisk - vest blokk gastro</name>
      <address>
        <city>Haugesund</city>
        <zip>5504</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevål Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halmstad Hospital</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Surgery, University Hospital Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>S-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>Germany</country>
  </removed_countries>
  <results_reference>
    <citation>Freeman ML. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP. 2002 Nov;3(6):169-76. Review.</citation>
    <PMID>12432183</PMID>
  </results_reference>
  <results_reference>
    <citation>Demols A, Deviere J. New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines. JOP. 2003 Jan;4(1):49-57. Review.</citation>
    <PMID>12555016</PMID>
  </results_reference>
  <results_reference>
    <citation>Testoni PA. Preventing post-ERCP pancreatitis: where are we? JOP. 2003 Jan;4(1):22-32. Review.</citation>
    <PMID>12555013</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariani A. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? JOP. 2003 Jan;4(1):68-74. Review.</citation>
    <PMID>12555018</PMID>
  </results_reference>
  <results_reference>
    <citation>Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91.</citation>
    <PMID>12806612</PMID>
  </results_reference>
  <results_reference>
    <citation>Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion. 1993;54(2):105-11.</citation>
    <PMID>8319838</PMID>
  </results_reference>
  <results_reference>
    <citation>Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg. 2001 Sep;88(9):1178-82.</citation>
    <PMID>11531863</PMID>
  </results_reference>
  <results_reference>
    <citation>Moretó M, Zaballa M, Casado I, Merino O, Rueda M, Ramírez K, Urcelay R, Baranda A. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc. 2003 Jan;57(1):1-7.</citation>
    <PMID>12518122</PMID>
  </results_reference>
  <results_reference>
    <citation>Harrison LI, Riedel DJ, Machacek JH, Crowley JK, Kanniainen CM, Hoglin JA, Robison TS, Zumhofe JM. Bioequivalence Comparison of Two Drug-in-Adhesive Transdermal Nitroglycerin Patches. Am J Ther. 1996 Aug;3(8):580-585.</citation>
    <PMID>11862294</PMID>
  </results_reference>
  <results_reference>
    <citation>Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs. 2003;63(17):1799-812. Review.</citation>
    <PMID>12921486</PMID>
  </results_reference>
  <results_reference>
    <citation>Freeman ML. Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents? Gastroenterology. 2003 Jun;124(7):1977-80.</citation>
    <PMID>12806633</PMID>
  </results_reference>
  <results_reference>
    <citation>Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991 May-Jun;37(3):383-93. Review.</citation>
    <PMID>2070995</PMID>
  </results_reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>October 16, 2007</last_update_submitted>
  <last_update_submitted_qc>October 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2007</last_update_posted>
  <keyword>Pancreatitis</keyword>
  <keyword>Cholangiopancreatograpy, Endoscopic Retrograde/adverse</keyword>
  <keyword>Nitroglycerin</keyword>
  <keyword>Randomized Controlled Trial,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

